PMID

Data

Article Title

Organization

Structural Requirements for CNS Active Opioid Glycopeptides.

The University of Arizona

Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.

The University of Arizona

Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.

The University of Arizona

Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

The University of Arizona

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

The University of Arizona

Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.

The University of Arizona

Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells.

The University of Arizona

Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.

The University of Arizona

A sucrose-derived scaffold for multimerization of bioactive peptides.

The University of Arizona

Development of sulfonamide AKT PH domain inhibitors.

The University of Arizona

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

The University of Arizona

Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.

The University of Arizona

Ψ and χ Angle Constrains at the C-Terminus Trp Position of the Melanotropin Tetrapeptide Ac-His-d-Phe-Arg-Trp-NH

The University of Arizona

Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.

The University of Arizona

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.

The University of Arizona

Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.

The University of Arizona

Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand.

The University of Arizona

De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.

The University of Arizona

An update on sphingosine-1-phosphate receptor 1 modulators.

The University of Arizona

Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.

The University of Arizona

Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies.

The University of Arizona

Design of MC1R Selectiveγ-MSH Analogues with Canonical Amino Acids Leads to Potency and Pigmentation.

The University of Arizona

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.

The University of Arizona

Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same

Sk Biopharmaceuticals

Imidazopyrazine compounds, preparation methods and uses thereof

Dongguan Zhenxing-Beite Medicine Technology